Chinese Yeast Factory Boosts Cancer Drug Production 1000 Times
Key Insights
A Zhejiang University (search) team engineered brewer's yeast to produce 164.9 mg/L of catharanthine (search), the direct precursor to the anticancer drug vinblastine, inside a fermenter.
This output is nearly 1,000 times higher than any previously published global figure, breaking a decades-long supply bottleneck for the costly drug.
Vinblastine has been sourced exclusively from the Madagascar periwinkle, requiring up to 2 tonnes of dried leaves to yield just 1 gram, making it more expensive than gold by weight.
A research team at Zhejiang University (search) (ZJU) has cracked a molecular puzzle, turning ordinary yeast into a powerful factory for an expensive cancer drug and boosting its production by a thousand times. The findings were published by the peer-reviewed journal Science on July 16.
The anticancer drug vinblastine has long been sourced exclusively from the Madagascar periwinkle (Catharanthus roseus) plant. But it takes up to 2 tonnes of dried leaves to yield just 1 gram (0.03 ounce) of vinblastine, making it more expensive than gold by weight. This extreme scarcity has kept the drug costly and its supply unreliable for decades.
After years of work, a team led by ZJU professor Lian Jiazhang, in collaboration with Qu Yang's research group at the University of New Brunswick in Canada and Wang Yajie's team at Westlake University (search), has broken the deadlock.
They engineered brewer's yeast to produce 164.9 milligrams per litre (0.022 ounces per gallon) of catharanthine (search) — the direct precursor to vinblastine — inside a fermenter. That is nearly 1,000 times higher than any previously published global figure.
The foundation for this breakthrough was laid in 2022, when Lian's team first inserted the 30-step synthesis pathway for vinblastine into yeast. But for a long time, output stayed at just micrograms per litre, a fraction of what would be useful for commercial scale.
In a video from the ZJU-Hangzhou Global Scientific and Technological Innovation Centre, Lian explained the problem: "It came down to the cell's internal structure. One intermediate in the vinblastine pathway is highly unstable."